Moreover, based on the suggested interplay existing between TCF4 and HDACs in sustaining/suppressing peculiar transcriptional programs, HDAC inhibition could represent an effective strategy to impair the TCF4 repressive function and unlock the prodifferentiative potential of GBM CSCs, finally affecting tumor aggressiveness. The gene discussed is TCF4; the disease is glioblastoma.